BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Crystallics - a New Company Spinout with a Long History in Pharmaceutical Development


4/19/2011 9:49:53 AM

Amsterdam, The Netherlands, April 19, 2011 / B3C newswire / – Avantium Pharma BV, a leader in solid state research and pre-formulation for the pharmaceutical industry over the last 11 years, has been spun out from Avantium Holding BV in a management buy-out to create Crystallics.

The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract manufacturing organizations and agrochemical companies. Gunnar Staaf, Chief Executive Officer, commented: “Crystallics’ core business focus will be in solid state research and pre-formulation, an area where we have built up considerable expertise over the last decade. I believe our proprietary technology, experienced team, together with a strong customer focus, make Crystallics an ideal partner.”

Solid state research plays a central role in the pharmaceutical industry. Active pharmaceutical ingredients can exist in a number of solid forms, such as polymorphs, salts, co-crystals, hydrates, or amorphous forms. Various solid state forms of the same active pharmaceutical ingredient will have different characteristics that can have a significant impact on the safety and efficacy of a drug product. Marcel Hoffmann, Chief Scientific Officer, said: “We believe in a tailored, science based approach to meet the customer’s project objectives and budgets. Quality and speed will be at the heart of our research approach.”

About Crystallics - www.crystallics.com

Crystallics is a science driven contract research organization specializing in pre-formulation and identification of the physical forms of drug substances, including polymorphs, salts, co-crystals and amorphous phases. Screening, characterization and selection of solid forms, as well as crystallization process development and optimization are the main focus.

Crystallics has developed a number of unique and proprietary technologies both in hardware and software, including High Throughput X-ray Powder Diffraction (HT-XRPD) technology and laboratory informatics, data analysis and predictive models. These unique, proprietary technologies, together with a strong customer focus, make Crystallics the supplier of choice for solid state research and pre-formulation. Over the last decade, the vast majority of large and medium sized pharmaceutical companies, as well as, many smaller biotechnology companies have commissioned solid state and pre-formulation work with Crystallics.

Crystallics’ services include:

- Polymorph / salt / co-crystal screening

- Amorphous solid dispersions

- Solid form selection and characterization

- Pre-formulation studies

- Crystallization process development and optimization

- Intellectual Property consultancy

About Avantium - www.avantium.com

Avantium is a leading technology company specialized in the area of advanced high-throughput research and development. The company develops and commercializes YXY – its new brand name for chemical building blocks for making green materials and fuels that can compete on price and performance. Avantium has demonstrated the value and commercial potential of its unique technology and knowledge by collaborating with leading companies in the energy and chemical industries. Avantium has a global customer base for its profitable research and development services and systems offering, including market leaders such as BP, Shell and Sasol. Avantium offices and headquarters are based in Amsterdam, The Netherlands.

For more information about Avantium, please contact Mariëtte Hoogendoorn on +31 20 586 8010 or visit the corporate website www.avantium.com or the product website www.yxy.com.

Contact

Contact: Gunnar Staaf, CEO

Tel: +31 20 820 2690

Cell: +31 646 799 419

Email: gunnar.staaf@crystallics.com

Web: www.crystallics.com


Read at BioSpace.com


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->